

| | |
|-------------------------|--------------|
| Reference: | FOI.14495.24 |
| Subject: | Medications |
| Date of Request: | 23 May 2024 |

Requested:

1. How many patients has your trust treated in the past six months (for any disease) with the following drugs:

| Drug Name | Patient Number |
|--|-----------------------|
| Aubagio (teriflunomide) | |
| Avonex (interferon beta-1a) | |
| Betaferon (interferon beta-1b) | |
| Brabio (glatiramer acetate) | |
| Copaxone (glatiramer acetate) | |
| Extavia (beta interferon-1b) | |
| Gilenya (fingolimod) | |
| Kesimpta (ofatumumab) | |
| Lemtrada (alemtuzumab) | |
| Mavenclad (cladribine) | |
| Mayzent (siponimod) | |
| Ocrevus (ocrelizumab) | |
| Plegridy (peginterferon beta-1a) | |
| Ponvory (ponesimod) | |
| Rebif (beta interferon-1a) | |
| Tecfidera (dimethyl fumarate) | |
| Tysabri (natalizumab) | |
| Tysabri (natalizumab) Pre-filled syringes only | |
| Vumerity (diroximel fumarate) | |
| Zeposia (ozanimod) | |

2. How many patients has you trust treated with Rituximab for MS (Multiple Sclerosis) in the past six months?

3. How many patients within your trust have a diagnosis of MS (Multiple Sclerosis)?

4. Of the patients with a diagnosis of Multiple Sclerosis, how many patients have a diagnosis of:

| Condition | Patient Number |
|---|-----------------------|
| RRMS – Relapse Remitting Multiple Sclerosis | |
| PPMS – Primary Progressive Multiple Sclerosis | |
| SPMS – Secondary Progressive Multiple Sclerosis | |

Response:

1. Hywel Dda University Health Board (UHB) provides, within the table below, the number of patients that have been treated for any disease with the following drugs, from 1 November 2023 to 30 April 2024.

| Drug Name | Patient Numbers |
|--|------------------------|
| Aubagio (teriflunomide) | 0 |
| Avonex (interferon beta-1a) | 0 |
| Betaferon (interferon beta-1b) | 0 |
| Brabio (glatiramer acetate) | 0 |
| Copaxone (glatiramer acetate) | 0 |
| Extavia (beta interferon-1b) | 0 |
| Gilenya (fingolimod) | 0 |
| Kesimpta (ofatumumab) | 0 |
| Lemtrada (alemtuzumab) | 0 |
| Mavenclad (cladribine) | * |
| Mayzent (siponimod) | 0 |
| Ocrevus (ocrelizumab) | 0 |
| Plegridy (peginterferon beta-1a) | 0 |
| Ponvory (ponesimod) | 0 |
| Rebif (beta interferon-1a) | 0 |
| Tecfidera (dimethyl fumarate) | * |
| Tysabri (natalizumab) | 0 |
| Tysabri (natalizumab) Pre-filled syringes only | 0 |
| Vumerity (diroximel fumarate) | 0 |
| Zeposia (ozanimod) | * |
| Total | ** |

Where the figures in the table have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low numbers of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB has also replaced totals which could be used to calculate the redacted figure with a double asterisk (**). The UHB is therefore withholding this detail under Section 40(2) of the FoIA. This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

2. 3. & 4. Hywel Dda University Health Board (UHB) regrets to inform you that it does not hold the information requested.

The MS service is managed by Swansea Bay University Health Board (SBUHB). Therefore, we recommend that you redirect your request to the Freedom of Information Team at SBUHB. The contact details are as follows:

FOIA.Requests@wales.nhs.uk or alternatively, you can contact: FOIA Team, Swansea Bay University Health Board, Health Board Headquarters, 1 Talbot Gateway, Port Talbot, SA12 7BR.